Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design

Vladimir A. Karginov*, Ekaterina M. Nestorovich†, Mahtab Moayeri‡, Stephen H. Leplla§, and Sergey M. Bezrukov§

*Innovative Biologies, Inc., 10900 University Boulevard, Manassas, VA 20110; †Laboratory of Physical and Structural Biology, National Institute of Child Health and Human Development, and §Bacterial Toxins and Therapeutics Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892

Communicated by John B. Robbins, National Institutes of Health, Bethesda, MD, August 26, 2005 (received for review April 26, 2005)

Bacillus anthracis secretes three polypeptides: protective antigen (PA), lethal factor (LF), and edema factor (EF), which interact at the surface of mammalian cells to form toxic complexes. LF and EF are enzymes that target substrates within the cytosol; PA provides a heptameric pore to facilitate LF and EF transport into the cytosol. Other than administration of antibiotics shortly after exposure, there is currently no approved effective treatment for inhalational anthrax. Here we demonstrate an approach to disabling the toxin: high-affinity blockage of the PA63 pore by a rationally designed low-molecular-weight compound that prevents LF and EF entry into cells. Guided by the sevenfold symmetry and predominantly negative charge of the PA pore, we synthesized small cyclic molecules of sevenfold symmetry, β-cyclodextrins chemically modified to add seven positive charges. By channel reconstitution and high-resolution conductance recording, we show that per-6-(3-aminopropylthio)-β-cyclodextrin interacts strongly with the PA pore lumen, blocking PA-induced transport at subnanomolar concentrations (in 0.1 M KCl). The compound protected RAW 264.7 mouse macrophages from cytotoxicity of anthrax lethal toxin (≡ PA + LF). More importantly, it completely protected the highly susceptible Fischer F344 rats from lethal toxin. We anticipate that this approach will serve as the basis for a structure-directed drug discovery program to find new and effective treatments for anthrax.

infectious diseases | membrane transport | modified cyclodextrins

Anthrax infections are difficult to treat because flu-like symptoms appear only after the bacteria have multiplied inside the human host and started to produce the tripartite toxin that eventually causes death (1, 2). If antibiotics are applied at this stage, the infection can still be lethal because of the accumulation of the toxins. Logically, an effective therapeutic approach would include simultaneous blocking of bacterial growth by antibiotics and neutralization of anthrax toxin with antitoxins (2–5). Extensive research efforts both before and after the anthrax attacks of 2001 have made anthrax toxin one of the best-understood channel-mediated protein translocation systems (refs. 6–10 and references therein). Protective antigen (83 kDa, PA63) binds to specific cellular receptors, and after being cleaved by a furin-like protease of the host cell into two fragments, PA20 and PA63, the latter self-assembles to form a ring-shaped heptameric prepore (11) that can simultaneously bind up to three molecules of lethal factor (LF) and/or edema factor (EF). The complex is then endocytosed and trafficked to an intracellular compartment where acidic conditions induce conversion of the prepore to a pore (9), and EF and LF are translocated into the cytosol presumably by using the PA63 channel as a tunnel (12, 13).

Ongoing studies of the anthrax toxin system (summarized in refs. 3 and 9) have yielded promising new approaches to therapy and prophylaxis of anthrax. Therapies under development include toxin-neutralizing antibodies, receptor decoy-based antitoxins, blocking of PA cleavage and oligomerization, and inhibition of LF and EF association with the PA63 prepore (3). A polypeptide inhibitor that binds to the heptameric PA63 prepore and prevents the interaction between cell-binding and enzymatic moieties has been reported (14). Dominant-negative mutants of protective antigen that co-assemble with the wild-type PA63 protein and block its ability to translocate the LF and EF across membranes have also been developed (15). Here we propose another way to prevent LF and EF translocation inside the cell that involves blocking the PA63 channel with specially designed low molecular weight compounds. As a starting point for the development of high-affinity blockers of the PA63 pore we have used β-cyclodextrin, a cyclic molecule with a hydrophobic cavity.

The idea to use β-cyclodextrin derivatives as inhibitors of anthrax was based on a wealth of earlier research. The high-affinity blockage of transmembrane channels formed by infectious agents has been achieved previously, with probably the most prominent example being the anti-influenza drug amantadine (16). In the particular case of heptameric pores, it was found that the pore of staphylococcal α-hemolysin can be partially blocked by β-cyclodextrin (17) and that tetraalkylammonium cations block the ion conductance of the PA63 channel (18), interacting with the negative charges of the PA63 pore lumen (11, 19). Guided by these findings, several cationic β-cyclodextrin derivatives as candidate antitoxins were custom-synthesized (20). Here we describe the protective action of one of these compounds, per-6-(3-aminopropylthio)-β-cyclodextrin (AmPrβCD), demonstrated on both single-molecule and whole-organism levels.

Materials and Methods

Chemicals. Recombinant Bacillus anthracis LF and PA were produced as described in ref. 21 or acquired from List Biological Laboratories (Campbell, CA). β-Cyclodextrin and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma, and AmPrβCD was custom synthesized at Pinnacle Pharmaceuticals (Charlottesville, VA). The following chemical reagents were used: KCl, KOH, and HCl (Sigma); EDTA (ResGen); “purum” hexadecane (Fluka); diphytanoyl phosphatidylethanol (Avanti Polar lipids); and pentane (Burdick and Jackson).

Channel Reconstitution. “Solvent-free” bilayer lipid membranes were formed on a 60-μm-diameter (for single-channel measurements) or 150-μm-diameter (for multichannel measurements)
aperture in the 15-μm-thick Teflon film that separated two compartments as described elsewhere (22). PA₆₃ was prepared from PA₆₃ by limited trypsin digestion (23). Single channels were formed by adding 0.5–1 μl of 20 μg/ml stock solution of PA₆₃ to 1.5 ml of aqueous phase in the cis half of the chamber. For multichannel experiments we applied 1–2 μl of 0.2 mg/ml stock PA₆₃ to the cis side of the membrane. Using this protocol, we have found that PA₆₃ insertion was always directional. The applied potential is defined as positive if it is higher at the side of PA₆₃ addition.

**Cytotoxicity Assays.** RAW 264.7 cells (American Type Culture Collection) were grown in DMEM with 10% FCS, 2 mM Glutamax, 2 mM Hepes, and 50 μg/ml gentamycin (all from Invitrogen) at 37°C in a 5% CO₂/95% air atmosphere. Twofold dilutions of compound in DMEM were added to cells for 10 min, followed by addition of medium or lethal toxin (LeTx; PA plus LF) at three different concentrations. Cells treated with LeTx alone, at each of these concentrations, served as positive cytotoxicity controls. All experiments were done in duplicate. Cells were incubated for 3 h at 37°C, followed by addition of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to a final concentration of 0.5 mg/ml. After an additional 45-min incubation, all medium was removed, and cells were dissolved in 50 μl of 0.5% (wt/vol) SDS/25 mM HCl, in 90% (vol/vol) isopropyl alcohol. The plates were vortexed, and the oxidized MTT was measured as A₅₇₀ by using a microplate reader. Percent viability was calculated as a percentage of medium-treated controls. EC₅₀ values for protection curves were calculated by using PRISM 4.0 software (GraphPad, San Diego).

**Animal Experiments.** Male Fischer F344 rats (150 g) (Taconic Farms) were injected intravenously (200 μl) in groups of three with LeTx (10 μg of PA plus 10 μg of LF) in PBS, or in PBS containing AmPrβCD (0.25 mg or 1.25 mg per rat). A separate group of three rats were preinjected with AmPrβCD (1.25 mg per rat, intravenously, in 200 μl of PBS) 30 min before injection of LeTx (10 μg of PA plus 10 μg of LF). Animals were monitored continuously during the first 8 h for signs of malaise and for survival, and twice daily thereafter, for 7 days. All animal experiments were performed according to approved National Institute of Allergy and Infectious Diseases animal care protocols.

**Results and Discussion**

Seven D-glucose units comprise a β-cyclodextrin molecule (Fig. 1A Left) which has sevenfold symmetry (24), like the heptameric PA₆₃ prepore (11) (Fig. 1A Right), and an outer diameter of 15 Å. This diameter is comparable to the PA₆₃ prepore internal diameter of 20–35 Å (11) and the diameter of the reconstituted pore, which is at least 11 Å at its most narrow part (25, 26). Advanced methods exist for selective modification of cyclodextrins, and these offer established routes for synthesis of appropriate derivatives (27), for which many pharmaceutical applications have been described (28).

**Inhibition of PA₆₃ Channels in Planar Lipid Bilayers.** We first reconstituted anthrax PA₆₃ pores into planar lipid bilayers to study the effects of AmPrβCD on conductance of multichannel membranes and single channels. In both cases we found a profound inhibition of PA₆₃-induced conductance. Fig. 1B shows that addition of AmPrβCD to the cis side of a membrane containing 60 PA₆₃ channels in 0.1 M KCl caused a significant decrease in membrane conductance at extremely low (3 nM) AmPrβCD concentrations. The process advances in a steplike manner (see Fig. 1B Inset) with an amplitude of 87 ± 13 pS that coincides with the PA₆₃ channel conductance in 0.1 M KCl, showing that AmPrβCD acts on individual channels. Note also that the steady state of multichannel PA₆₃ conductance before AmPrβCD addition is rather noisy. This noisiness could be explained by the well known “voltage gating” of PA₆₃ channels (25), which tend to stay closed at relatively high voltages but occasionally switch to the closed state even at 20 mV. Moreover, PA₆₃ channels exhibit a much faster flickering between the open and closed states (see ref. 18 for details) that also contributes to the fluctuations seen around the steady-state conductance.

Quantitative analysis of the single-channel blockage proved difficult at these physiological salt concentrations because the residence time of the compound in the channel was very long (minutes). Fig. 1B (Inset) represents the consecutive cutoffs of the channels in a multichannel membrane and the step’s lifetime is on the order of seconds. This time, however, reflects only the “on-rate” of the AmPrβCD–PA₆₃ association reaction. To be able to obtain reliable statistics on the “off-rate,” we switched to 0.3 M and higher salt concentrations. This switch allowed us to more fully characterize and quantify this process on a single-channel level. Typical recordings of ion current through a single PA₆₃ pore in 1 M KCl are shown in Fig. 2. A single PA₆₃ oligomer spontaneously inserts as an oriented channel showing gating at applied voltages (12, 25) (Fig. 2, topmost track). Addition of 13 nM AmPrβCD to the cis side of the membrane (side of toxin...
addition) caused additional fluctuations in the current through a single channel (Fig. 2, second track). These fluctuations are fast transients between a fully open and blocked channel. Increasing the AmPr\textsubscript{2CD} concentration to 80 nM and 1.8 \textmu M increased the probability of finding the channel in the blocked state (Fig. 2, two lower tracks, and Fig. 3 \textit{A}). Note that within the accuracy of our measurements we find that the blockage is complete. It is different, therefore, from the \textit{β}-cyclodextrin effect on \textit{α}-hemolysin channels (17), where the blockage is only about 70%.

We found that the binding parameters for this process strongly depend on at least three factors: applied transmembrane voltage (Fig. 3 \textit{A}), bathing electrolyte concentration (Fig. 3 \textit{B} and \textit{C}), and lipid charge (data not shown). Fig. 3 \textit{A} illustrates the probability of finding the channel in a completely blocked state as a function of voltage at various AmPr\textsubscript{2CD} concentrations. The probabilities were calculated from the data analogous to that shown in Fig. 2. It is seen that high negative voltages from the side opposite to AmPr\textsubscript{2CD} addition drag the positively charged AmPr\textsubscript{2CD} into the channel. We propose that these stepwise transitions reflect the complete blockage of the channel as a result of reversible binding of the positively charged AmPr\textsubscript{2CD} to the negatively charged residues inside the PA\textsubscript{63} pore lumen. The involvement of electrostatic interactions is suggested by the strong dependence of blockage parameters on salt concentration. High salt concentrations reduce electrostatic forces significantly, most probably screening out charges on both the blocker and the protein. This screening leads to a decrease in the residence time by orders of magnitude (Fig. 3\textit{C}). In 1 M KCl the “electrical distance” (18) to the blockage site, as calculated from the data in Fig. 3A and assuming that AmPr\textsubscript{2CD} has a charge of +7, is only \begin{math} \approx \end{math} 15%.

Fig. 4 gives a typical example of a titration curve in a multichannel experiment in 1 M KCl. Fig. 4B summarizes inhibition of PA\textsubscript{63}-induced conductance for three different KCl concentrations: 0.1, 1.0, and 2.5 M. Remarkably, in “physiological” 1 M solutions, the 50\% inhibitory concentration (IC\textsubscript{50}) is 0.55 nM. These data are complemented by single-channel analysis that shows a significant increase of AmPr\textsubscript{2CD}-PA\textsubscript{63} binding time with lowering of KCl concentration (Fig. 3 \textit{B} and \textit{C}).

Previous studies demonstrated that tetraalkylammonium ions, ranging in size from tetramethylammonium to tetrahexylammonium, reduced membrane macroscopic conductance (>1,000 PA\textsubscript{63} channels) at micromolar concentrations when added on either the cis (protein-containing) or trans side of the membrane (18, 26). Similar results were recently reported for chloroquine and related compounds (29), which induced multichannel conductance reduction with IC\textsubscript{50} of \approx 0.1 \textmu M. In the present work we demonstrate that a rationally designed low molecular weight compound, AmPr\textsubscript{2CD}, is a 100- to 1,000-fold more potent blocker of anthrax channels [compare IC\textsubscript{50} of 0.55 nM found in the present study for AmPr\textsubscript{2CD} with 81 nM for quinacrine (29) and 2.04 \textmu M for pentaalkylammonium (26)].

Exploration of the blockage phenomenon at the level of a single PA\textsubscript{63} channel with tetrabutylammonium ion (Bu\textsubscript{4}N\textsuperscript{+}) (18) showed that Bu\textsubscript{4}N\textsuperscript{+} induces blockage of the pore when present on either side of the membrane. The voltage dependence of dwell times allowed the authors to speculate that Bu\textsubscript{4}N\textsuperscript{+} is driven...
through the channel by voltage and binds to the same blocking site within the channel lumen. Correspondingly, we believe that AmPr/H9252CD interrupts the current through the PA63 pore as a result of strong interaction of the positively charged amino groups with the negatively charged residues inside the channel. We find that AmPr/H9252CD blocks ion current through the pore very effectively when added to cis, trans, or both sides of the membrane (data not shown). This observation shows that the AmPr/H9252CD molecule is able to enter the channel from both extracellular and intracellular openings.

In comparison with AmPr/H9252CD, the nonmodified neutral/H9252-cyclodextrin displayed only weak binding affinity when added from the trans (intracellular and, therefore, physiologically irrelevant) residence times for 0.75 and 2.5 M KCl. (C) Correlation between AmPr/H9252CD residence time and KCl concentration at 100-mV applied voltage. The residence time is obtained by the single-exponential fitting as illustrated in B. Error bars represent root-mean-square deviations of estimates obtained by using different search, minimization, and weighting fitting methods available within the CLAMPFIT 9.2.0.10 program (Axon Instruments).
only weakly to a heptameric α-hemolysin channel (17) and to connexin channels reconstituted in unilamellar liposomes (30). The previous studies showed that the nonmodified β-cyclodextrin can enter the channels and reach its binding site from the cytoplasmic side but not from the side that is normally extracellular. Here we successfully designed and tested a derivative that is able to effectively block PA63 channel by entry into the pore lumen from the extracellular side of the membrane.

**Inhibition of Lethal Toxin in Cells and Animals.** The strong binding of AmPrβCD to the PA63 channel demonstrated in the channel reconstitution experiments above implied that the candidate drug would block LeTx action in biological systems. We evaluated the ability of AmPrβCD and nonmodified β-cyclodextrin to inhibit the cytotoxic effect of LeTx on the mouse macrophage-like RAW 264.7 cell line. Macrophages were treated with 2-fold dilutions of either compound for 10 min before addition of set concentrations of LeTx. Medium-treated control cells also received the same LeTx concentrations, which served as positive cytotoxicity controls. Cells treated with medium alone served as negative cytotoxicity controls. Whereas nonmodified β-cyclodextrin did not show protection against LeTx up to 100 μM concentrations, the cationic AmPrβCD protected against LeTx action in a manner dependent on the PA concentration (Fig. 5A). The calculated IC50 values for AmPrβCD protection against LeTx under the 3-h assay conditions used were 4.25 μM, 1.61 μM, and 0.278 μM for PA concentrations of 1,000 ng/ml (12 nM), 500 ng/ml (6 nM), and 200 ng/ml (2.4 nM), respectively. Controls treated with drug alone indicated that AmPrβCD was not toxic to RAW 264.7 cells up to 37.5 μM but showed increasing toxicity at higher concentrations, with a killing EC50 of ~150 μM.

Finally, we evaluated the efficacy of this compound in the highly LeTx-sensitive Fischer F344 rat. Whereas control rats injected with LeTx (10 μg of PA plus 10 μg of LF) died in 77–83 min, rats treated with toxin and AmPrβCD (1.25 mg per rat) were fully protected and showed no signs of malaise (Fig. 5B). This amount of compound corresponds to ~40–50 μM in the rat circulation (based on 12–15 ml per rat), whereas the concentration of PA in the animals, based on the same volume, is 8–10 nM, indicating a >1,000-fold molar excess of drug. A 5-fold lower concentration of AmPrβCD was not effective in protecting the rats, although it did extend their survival significantly, to an average of ~200 min (Fig. 5B). Interestingly, pretreatment of the rats with 1.25 mg of AmPrβCD 30 min before LeTx challenge was also fully protective. This group of rats, however, showed some signs of malaise, indicating shortness of breath and lethargic behavior for 6–8 h, before full recovery.

In conclusion, we believe the data presented here illustrate the value of a structure-based drug design that exploits unique features of the target molecule. The oligomeric nature of the central component of anthrax toxin, the PA63 heptamer, enabled us to dock to it, with high affinity, a complementary oligomeric compound of low molecular weight. This approach can be extended to the design of inhibitors of other toxins and protein channels that play key roles in the action of pathogenic bacteria.

We are grateful to Adrian Parsegian for valuable discussions and comments. We thank Mr. Jason Wiggins for help with animal experiments. This research was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Child Health and Human Development and National Institute of Allergy and Infectious Diseases and by Grant 1R43AI052894-01 from the National Institute of Allergy and Infectious Diseases.